Subtopic Deep Dive

Low-Dose CT Screening for Lung Cancer
Research Guide

What is Low-Dose CT Screening for Lung Cancer?

Low-dose CT (LDCT) screening uses reduced radiation helical CT scans to detect early-stage lung cancer in high-risk smokers, reducing mortality by 20% as shown in the NLST trial (Aberle et al., 2011).

The National Lung Screening Trial (NLST) demonstrated 20% lung cancer mortality reduction with LDCT versus chest X-ray in 53,454 high-risk participants (Aberle et al., 2011; 10,624 citations). The Dutch-Belgian NELSON trial confirmed 25% mortality reduction with volume CT screening (de Koning et al., 2020; 3,212 citations). Key datasets like LIDC-IDRI enable nodule detection research (Armato et al., 2011; 2,623 citations).

15
Curated Papers
3
Key Challenges

Why It Matters

LDCT screening established USPSTF guidelines for annual screening in adults aged 50-80 with 20 pack-year history, implemented in millions and reducing population mortality (Krist et al., 2021). Risk models from PanCan study estimate nodule malignancy probability, guiding biopsy decisions and cutting unnecessary procedures (McWilliams et al., 2013). LIDC-IDRI dataset supports AI development for automated nodule analysis, improving radiologist accuracy (Armato et al., 2011). Cost-effectiveness analyses from NLST support program scalability (Gatsonis et al., 2010).

Key Research Challenges

Overdiagnosis in LDCT

LDCT detects indolent cancers that may not progress, inflating incidence without mortality benefit (Aberle et al., 2011). Balancing sensitivity and specificity remains critical in high-risk cohorts (de Koning et al., 2020).

Nodule Malignancy Prediction

Pulmonary nodules require accurate risk stratification to avoid overtreatment; PanCan model uses size, location, and patient factors (McWilliams et al., 2013). Validation across diverse populations is limited (Henschke, 2006).

Cost-Effectiveness Scaling

High false-positive rates drive follow-up costs, challenging program implementation (Gatsonis et al., 2010). NELSON trial shows lower rates but broader adoption needs economic modeling (de Koning et al., 2020).

Essential Papers

1.

Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

Unknown, Denise R Aberle, Amanda M Adams et al. · 2011 · New England Journal of Medicine · 10.6K citations

Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385.).

2.

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

William D. Travis, Élisabeth Brambilla, Masayuki Noguchi et al. · 2011 · Journal of Thoracic Oncology · 4.8K citations

3.

Lung cancer: current therapies and new targeted treatments

Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine et al. · 2016 · The Lancet · 3.3K citations

4.

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

Harry J. de Koning, Carlijn M. van der Aalst, Pim A. de Jong et al. · 2020 · New England Journal of Medicine · 3.2K citations

In this trial involving high-risk persons, lung-cancer mortality was significantly lower among those who underwent volume CT screening than among those who underwent no screening. There were low ra...

5.

The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): A Completed Reference Database of Lung Nodules on CT Scans

Samuel G. Armato, Geoffrey McLennan, Luc Bidaut et al. · 2011 · Medical Physics · 2.6K citations

Purpose: The development of computer‐aided diagnostic (CAD) methods for lung nodule detection, classification, and quantitative assessment can be facilitated through a well‐characterized repository...

6.

Survival of Patients with Stage I Lung Cancer Detected on CT Screening

Claudia I. Henschke · 2006 · New England Journal of Medicine · 1.7K citations

Annual spiral CT screening can detect lung cancer that is curable.

7.

Screening for Lung Cancer

Alex H. Krist, Karina W. Davidson, Carol M. Mangione et al. · 2021 · JAMA · 1.6K citations

The USPSTF recommends annual screening for lung cancer with LDCT in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Scr...

Reading Guide

Foundational Papers

Start with NLST (Aberle et al., 2011) for mortality proof, NLST design (Gatsonis et al., 2010) for methods, LIDC-IDRI (Armato et al., 2011) for data, PanCan (McWilliams et al., 2013) for nodules.

Recent Advances

NELSON (de Koning et al., 2020) for volume CT confirmation; USPSTF update (Krist et al., 2021) for guidelines; CheXNeXt (Rajpurkar et al., 2018) for AI augmentation.

Core Methods

Helical LDCT at 120 kVp/30-60 mAs; nodule assessment via size (>6mm follow-up), PanCan probability (age, sex, nodules); CAD on LIDC-IDRI with deep learning.

How PapersFlow Helps You Research Low-Dose CT Screening for Lung Cancer

Discover & Search

Research Agent uses searchPapers and citationGraph on 'NLST Aberle 2011' to map 10,624 citing papers, revealing NELSON extensions (de Koning et al., 2020); exaSearch uncovers risk models like PanCan via 'low-dose CT nodule probability'.

Analyze & Verify

Analysis Agent applies readPaperContent to extract NLST mortality HR=0.80 from Aberle et al. (2011), then verifyResponse with CoVe and runPythonAnalysis for meta-analysis of NLST/NELSON HRs; GRADE grading assesses NLST as high-quality RCT evidence.

Synthesize & Write

Synthesis Agent detects gaps in overdiagnosis mitigation post-NLST, flagging contradictions between Henschke (2006) survival and Aberle (2011) harms; Writing Agent uses latexEditText, latexSyncCitations for NLST review, latexCompile for export, exportMermaid for screening workflow diagrams.

Use Cases

"Compare mortality reductions in NLST vs NELSON trials with confidence intervals"

Research Agent → searchPapers('NLST NELSON mortality') → Analysis Agent → readPaperContent(Aberle 2011, de Koning 2020) → runPythonAnalysis(pandas meta-analysis of HRs/CIs) → researcher gets GRADE-graded table with forest plot.

"Write LaTeX section on LDCT nodule guidelines citing PanCan and LIDC"

Synthesis Agent → gap detection('nodule management LDCT') → Writing Agent → latexEditText('draft guidelines') → latexSyncCitations(McWilliams 2013, Armato 2011) → latexCompile → researcher gets PDF with synced bibtex.

"Find code for lung nodule CAD from LIDC-IDRI papers"

Research Agent → searchPapers('LIDC-IDRI CAD github') → Code Discovery → paperExtractUrls(Armato 2011) → paperFindGithubRepo → githubRepoInspect → researcher gets annotated repo list with nodule detection scripts.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers(250+ LDCT papers) → citationGraph(NLST cluster) → DeepScan(7-step: verify NLST claims via CoVe, Python survival analysis). Theorizer generates hypotheses on AI-reduced overdiagnosis from LIDC-IDRI + Rajpurkar (2018) CheXNeXt. Chain-of-Verification ensures zero hallucinations in mortality stats.

Frequently Asked Questions

What defines low-dose CT screening?

LDCT uses ≤1.5 mSv radiation for annual scans in high-risk smokers aged 55-74 with ≥30 pack-years, per NLST protocol (Aberle et al., 2011).

What methods prove LDCT efficacy?

Randomized trials NLST (20% mortality reduction, Aberle et al., 2011) and NELSON (25% reduction, de Koning et al., 2020); USPSTF endorses based on these (Krist et al., 2021).

What are key papers?

NLST (Aberle et al., 2011; 10k+ citations), NELSON (de Koning et al., 2020), LIDC-IDRI (Armato et al., 2011), PanCan nodules (McWilliams et al., 2013).

What open problems exist?

Reducing overdiagnosis/false-positives, refining risk models beyond PanCan for diverse groups, scaling cost-effective programs post-NLST/NELSON.

Research Lung Cancer Diagnosis and Treatment with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Low-Dose CT Screening for Lung Cancer with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.